.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ advanced breast cancer cells and also active or even stable mind metastases presented constant intracranial activity and also wide spread efficacy of T-DXd.